Breaking News
NEW WEBINAR | Empowering Patient Leaders: Understanding EU Health Policies
CLINICAL NEWS | Agios Meets Clinical Proof-of-Concept in Anaemia Treatment for Adults with Lower-Risk MDS
CASGEVY | 1st Gene-Editing Therapy for Thalassaemia and SCD Approved in UK
NEW VIDEO | Jo’s Story With β-Thalassaemia
BREAKING NEW GROUND | The First-Ever Guidelines for Managing α-Thalassaemia
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | LDH Improvements Lead to Better Outcomes in Fatigue and QoL
TIF’s NEW e-COURSE | Enhance Your Understanding of EU Health Policy
TIF2023 | 16th International Conference on Thalassaemia & Haemoglobinopathies, November 3-5
CLINICAL NEWS | Promising Outcomes Found with Stem Cell Transplant for Fanconi Anemia-related Leukemia, MDS
POSITION PAPER | Strengthening the Resilience of EU Health Systems
English
English
Ελληνικά
Français
Deutsch
Italiano
العربية
Menu
Home
Who we are
TIF History
Vision & Mission
Pillars of Work
Board of Directors
Staff Members
TIF Members
Collaborations
Transparency
Awards & Honours
What we do
Education
Country Work
Projects
Global Thalassaemia Review
COVID-19 Pandemic & TIF
Surveys
Haemoglobin Disorders
Thalassaemia
Sickle Cell Disease
Clinical Trial Updates
Positions & Policies
Policy Framework
Position Papers
Official Statements
Publications
TIF Publications
Scientific Literature
Additional Resources
Media Centre
News
Newsletters
Events
Videos
Contact us
Search for
Home
/
What we do
What we do
Back to top button
Close
Search for
